Incidence of Dyslipidemia Elevated During COVID-19 Pandemic
THURSDAY, Nov. 14, 2024 -- There was an increase in dyslipidemia incidence during the COVID-19 pandemic compared with the prepandemic period, according to a study published online Sept. 12 in the Journal of Clinical Investigation.
Valentina Trimarco, from Federico II University in Naples, Italy, and colleagues conducted a six-year longitudinal study to examine the broader effects of COVID-19 on the incidence of dyslipidemia in a real-world population of 228,266 individuals. Dyslipidemia incidence was compared during the COVID-19 pandemic (2020 to 2022) to the prepandemic period (2017 to 2019), with follow-up of at least 1,095 days (21,349,215 person-years).
The researchers found that the risk for developing dyslipidemia was increased during the COVID-19 period compared with the pre-COVID-19 period (odds ratio, 1.29), after adjustment for comorbidities in a multivariate analysis.
"The main finding of our study is the observation that the increased risk of dyslipidemia during the COVID-19 pandemic involved not only patients who had severe acute respiratory syndrome coronavirus 2 infection but the whole population," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Further Support and Information on COVID-19
Read this next
Prevention Strategies Developed for Cardiovascular Manifestations of COVID
FRIDAY, Sept. 26, 2025 -- Prevention strategies for cardiovascular manifestations of acute and long COVID are discussed in a report published online Sept. 18 in the European...
Long COVID Linked to Abnormal Uterine Bleeding
WEDNESDAY, Sept. 17, 2025 -- Long COVID is associated with abnormal uterine bleeding (AUB), but not with impaired ovarian function, according to a study published online Sept. 16...
Azelastine Nasal Spray Reduces Risk for SARS-CoV-2 Infection
FRIDAY, Sept. 5, 2025 -- Azelastine nasal spray is associated with a reduced risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.